Low Density Lipoprotein (LDL) News and Research

RSS

Clues to underlying causes of atherosclerosis

By changing the behavior of certain cells within human blood vessels, Cornell University researchers have discovered important clues as to the underlying causes of atherosclerosis - a discovery researchers hope can lead to more targeted drug therapies for the prevention of the disease.

8 Dec 2011

Report shows how mutant gene influences lipid metabolism

People who carry a malfunctioning copy of a particular gene are especially good at clearing fat from their systems. The report in the December Cell Metabolism, a Cell Press publication, shows how the mutant gene influences metabolism in this way.

7 Dec 2011

Watson commences shipping of generic LIPITOR

Watson Pharmaceuticals, Inc. today confirmed that Watson Pharmaceuticals, Inc., has launched an authorized generic version of LIPITOR (atorvastatin calcium tablets) as part of an exclusive agreement with Pfizer Inc.

30 Nov 2011

Ranbaxy receives FDA approval for first generic version of cholesterol-lowering drug Lipitor

The U.S. Food and Drug Administration today approved the first generic version of the cholesterol-lowering drug Lipitor.

30 Nov 2011

Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD

Resverlogix Corp. today announced that SUSTAIN, a Phase 2b clinical trial comprised of 176 subjects, is fully enrolled.

28 Nov 2011

Benefits of vitamin D-fortified yoghurt drink for people with diabetes

People with diabetes are known to have an increased risk of heart disease. New research published in BioMed Central's open access journal BMC Medicine shows that regular consumption of a vitamin D-fortified yoghurt drink improves cholesterol levels and biomarkers of endothelial dysfunction, a precursor of heart disease, in diabetics.

24 Nov 2011

Cambridge Theranostics' liquidators set deadline for offers

Cambridge Theranostics' liquidators have set a deadline of 9 December for offers for the company's business, which includes the intellectual property of its principal product, Ateronon.

21 Nov 2011

Psoriasis may alter cholesterol composition and decrease HDL function

Collaborative research from Perelman School of Medicine at the University of Pennsylvania has shown that psoriasis patients have an increased risk of heart attack, stroke and cardiovascular death, especially if the psoriasis is moderate to severe. Now, Penn researchers have discovered the potential underlying mechanism by which the inflammatory skin disease impacts cardiovascular health.

17 Nov 2011

Cholesterol drugs clash head on

Major cholesterol lowering drugs are being pitched against each other. The cheaper ones are more likely to win say experts.

16 Nov 2011

Rosuvastatin as effective as atorvastatin in reversing atherosclerosis

Maximum doses of Crestor- (rosuvastatin) or Lipitor- (atorvastatin) are similarly effective in reversing the buildup of cholesterol plaques in the coronary artery walls (atherosclerosis) after 24 months of treatment, according to Cleveland Clinic researchers.

16 Nov 2011

Niacin not effective in reducing risk of stroke, heart attack in stable CV patients

In patients whose bad cholesterol is very well-controlled by statins for a long time period, the addition of high-dose, extended release niacin did not reduce the risk of cardiovascular events, including heart attack and stroke.

16 Nov 2011

Evacetrapib drug may increase HDL-C and decrease LDL-C levels

Among patients with sub-optimal low-density lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C) levels, use of the drug evacetrapib alone or in combination with statin medications was associated with significant increases in HDL-C levels and decreases in LDL-C levels, according to a study appearing in the November 16 issue of JAMA, a theme issue on cardiovascular disease.

16 Nov 2011

Type 2 diabetics with low cholesterol may carry residual risk of cardiac events

LipoScience, Inc., an in-vitro diagnostic company advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary platform based on nuclear magnetic resonance (NMR) technology, recognizes a presentation of clinical data which suggests that type 2 diabetics with low non-HDL and low LDL cholesterol may carry residual risk of a cardiac event based on high LDL particle numbers.

16 Nov 2011

Link between sugar-sweetened beverages and increased cardiovascular risk in women

Drinking two or more sugar-sweetened beverages a day may expand a woman's waistline and increase her risk of heart disease and diabetes, according to research presented at the American Heart Association's Scientific Sessions 2011.

14 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Merck’s cholesterol lowering drug gets FDA panel’s vote

A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.

3 Nov 2011

Positive results from DARA's DB959 Phase 1b study on type 2 diabetes

DARA BioSciences, Inc., announces the positive results from a successfully completed Phase 1b clinical study for DB959, its peroxisome proliferator activated receptor (PPAR)-delta/gamma agonist, a non-TZD oral drug in development for the treatment of type 2 diabetes.

2 Nov 2011

Obama gets clean bill of health

President Barack Obama is in excellent health and tobacco free, his doctor said Monday in the results of the president’s second physical exam since taking office.

1 Nov 2011

BUSM professor delivers Van Meter Award Lecture at 81st ATA meeting

The American Thyroid Association (ATA) is proud to announce that Dr. Elizabeth Pearce, Associate Professor of Medicine at Boston University School of Medicine, today delivered the Van Meter Award Lecture at its 81st Annual Meeting, held October 26-30, Indian Wells, California.

1 Nov 2011

Gender not an independent predictor of mortality post-PCI

New research shows that women undergoing percutaneous coronary intervention (PCI), also known as angioplasty, exhibit more co-morbidities and cardiovascular risk factors than men. Risk-adjusted analyses have now indicated that, in the contemporary era, gender is not an independent mortality predictor following PCI according to the study now available in Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

1 Nov 2011